Breast lipoma

Summary

Breast lipoma (MONDO:0000970) is a disease. A subtype of breast benign neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	breast lipoma
Mondo ID	MONDO:0000970
DOID	DOID:10199
NCIT	C4647
SNOMED CT	276891009
UMLS	C0349565
MedGen	138103
Anatomy (UBERON)	UBERON:0000310
Is cancer (heuristic)	no

Also known as: breast lipoma · lipoma of breast · lipoma of the breast

Disease family

This is a subtype of breast benign neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › benign neoplasm › thoracic benign neoplasm › breast benign neoplasm › breast lipoma

Related subtypes (14): breast cyst, benign eccrine breast spiradenoma, breast fibroadenoma, breast leiomyoma, breast adenoma, breast myofibroblastoma, benign breast adenomyoepithelioma, breast hemangioma, multiple fibroadenoma of the breast, benign breast phyllodes tumor, intraductal breast papilloma, benign neoplasm of male breast, diabetic mastopathy, lymphocytic mastitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.